CMI-392 is used as a dual 5-lipoxygenase inhibitor and platelet-activating factor (PAF) receptor antagonist; it significantly reduces ear weight, inflammatory cell infiltration, and histological abnormalities in acute and chronic TPA-induced mouse ear inflammation models; it is effective in treating PAF-induced mouse hemoconcentration (ED50 = 2.2 mg/kg) and arachidonic acid-induced mouse ear edema (ED50 = 1.8 mg/kg).